UAE’s Julphar will set up its flagship Saudi unit in Modon 3rd Industrial City
UAE’s Julphar (Gulf Pharmaceutical Industries) has signed a long-term lease agreement with Modon 3rd Industrial City in Jeddah to establish its integrated pharmaceutical manufacturing facility in the Kingdom of Saudi Arabia.
Julphar is making a total investment of approximately SAR300 million (US$80 million) and will be developed on an area of 45,000 square meters. Once operational, the facility is expected to generate up to 1,400 jobs.
The facility is designed to serve as an export platform for US pharmaceuticals and other international markets. The location in Modon 3rd Industrial City was strategically chosen to ensure efficient supply chains, advanced facilities, and seamless access to both domestic and regional markets.
Julfar supports the Saudi Vision 2030 goals
This brings Julphar closer to its strategy of producing local medicines, strengthening national health security, and creating a regional hub for exporting pharmaceutical products to GCC countries and global markets. It also demonstrates the company’s commitment to supporting the goals of Saudi Vision 2030 through technology transfer, development of local industrial capabilities, and promoting independence within the pharmaceutical sector.
Sheikh Saqr bin Humaid Al Qasimi, Chairman of Julphar, commented: “The establishment of Julphar’s pharmaceutical manufacturing facility in the Kingdom of Saudi Arabia marks a milestone in our expansion journey.
“We are proud to contribute to Saudi Arabia’s industrial development and support the goals of Vision 2030 through technology transfer, localization of expertise, and creating sustainable industrial skills for future generations.”
Julphar will use advanced manufacturing technology covering sterile injectable and oral solid dosage (OSD) forms. The product portfolio will focus on biologics and specialty drugs in several areas of critical care and chronic diseases. The portfolio will continue to grow in line with the evolving needs of the Saudi and regional markets.
Dr. Basel Ziyadeh, Julphar’s Chief Executive Officer, added: “This project represents a long-term strategic investment to strengthen Julphar’s position as a leading pharmaceutical manufacturer in the MENA region and other international markets.”
“We are fully committed to applying the highest standards of quality and compliance and to developing qualified local talent, ensuring sustainable production and strengthening the global availability of Julphar products.”
